Find out why these three biotech stocks could be huge winners.
News & Analysis: Galectin Therapeutics
Galectin's new patent for its lead drug candidate sent its shares higher today.
Shares of Galectin Therapeutics and Verastem should both head higher in the coming week. Here's why.
The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.
Galectin shares soar following the company's dosing of its first patient in a second phase 1 cohort. Here's what shareholders should really be watching.
Consumer confidence hits a six-year high, adding fuel to the huge run-ups for Plug Power, Varonis Systems, and Galectin Therapeutics.
Galectin sets the date for the release of its phase 1 study data on GR-MD-02 for nonalcoholic steatohepatitis. Find out what shareholders should really be waiting for.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar Therapeutics
Top stories in biotech and healthcare today.
Why Inteliquent, Pacific Biosciences of California, and Galectin Therapeutics Are Today's 3 Best Stocks
The S&P 500 advances modestly on strong earnings results as Inteliquent, Pacific Biosciences of California, and Galectin Therapeutics jumped by at least 15%.